The Primary Biliary Cholangitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of ...

Research from earlier this year found that 80 per cent of England’s regional health bodies lacked an effective pathway to ...

Swedish researchers have discovered a new test which can detect risk of liver disease years before symptoms typically appear.

What is primary biliary cholangitis? Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the liver. It was previously known as primary biliary cirrhosis, but the name was changed as ...

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily ...

(MENAFN- GlobeNewsWire - Nasdaq) MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced ...

New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for treating primary biliary cholangitis.

As with other drugs, Livdelzi (seladelpar) can cause side effects, such as headache and abdominal pain. If side effects of Livdelzi become difficult to tolerate, talk with your doctor or pharmacist.

An update from Genfit SA ( ($GNFT) ) is now available. On September 22, 2025, GENFIT S.A. released its Half-Year Business and Financial Report for ...

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in ...